Organigram Holdings (TSXV:OGI; OTCQB:OGRMF) entered a partnership to provide front-line harm reduction workers in New Brunswick with a life-saving tool capable of reversing negative effects of opioids, including fentanyl overdose.
As quoted in the press release:
The partnership comes in response to an expressed need by community groups working under the Alliance of New Brunswick AIDS organizations. These groups work on the front lines of opioid addiction, providing needle exchange and additional services to opioid users in the province’s urban centres. Previously, these groups were unable to supply Naloxone kits (which range between $50 – $100 each) to their staff.
“Fentanyl use, misuse and overdose are an issue of major concern in Canada. We have watched the devastation in other parts of the country, and as part of our contribution to the health and welfare of New Brunswickers, we want to do what we can to help ensure our front-line teams are (better) equipped to handle the crisis,” says Organigram Chief Executive Officer Greg Engel.